{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T05:06:51Z","timestamp":1663650411420},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>It is important to analyze the types of vaccines in travel clinics to determine the focus points in future practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively reviewed the electronic medical records of all patients who visited the travel clinic of Nara Medical University between June 2013 and December 2019 to determine their background and the vaccines administered. The information regarding adverse events of the unapproved vaccines in Japan (Havrix<jats:sup>\u00ae<\/jats:sup>, Verorab<jats:sup>\u00ae<\/jats:sup>, Boostrix<jats:sup>\u00ae<\/jats:sup>, Priorix<jats:sup>\u00ae<\/jats:sup>, Typhim Vi<jats:sup>\u00ae<\/jats:sup>, and Mencevax<jats:sup>\u00ae<\/jats:sup>) was also collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 645 patients, 58.6% were men and the median age was 31 years. Business was the most common travel purpose (34.9%), and Southeast Asia was the most common destination (40.2%). More than 80% of travelers to low- and middle-income countries were vaccinated against hepatitis A, while the rabies vaccination rate was approximately 50%. Typhoid vaccination coverage among travelers to South Asia was approximately 50%. The incidence of adverse events requiring medical consultation, telephonic consultation, or prolonged stay in the examination room was less than 5% for all unapproved vaccines in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>More patient education is needed to increase the vaccination rate of rabies and typhoid vaccines. Adverse events to unapproved vaccines in Japan were not high and were well-tolerated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/med-2021-0303","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T20:11:08Z","timestamp":1625083868000},"page":"978-985","source":"Crossref","is-referenced-by-count":0,"title":["Travelers\u2019 vaccines and their adverse events in Nara, Japan"],"prefix":"10.1515","volume":"16","author":[{"given":"Taku","family":"Ogawa","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases, Nara Medical University , 840 Shijo-Cho Kashihara , Nara 634-8522 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyasu","family":"Hirai","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Nara Medical University , 840 Shijo-Cho Kashihara , Nara 634-8522 , Japan"},{"name":"Department of Pathogen, Infection and Immunity, Nara Medical University , Nara , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Imakita","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Nara Medical University , 840 Shijo-Cho Kashihara , Nara 634-8522 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujikura","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Nara Medical University , 840 Shijo-Cho Kashihara , Nara 634-8522 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kajita","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Nara Medical University , 840 Shijo-Cho Kashihara , Nara 634-8522 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Imai","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Nara Medical University , 840 Shijo-Cho Kashihara , Nara 634-8522 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University , Nara , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeyama","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University , Nara , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Nara Medical University , 840 Shijo-Cho Kashihara , Nara 634-8522 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"2022091918195049157_j_med-2021-0303_ref_001","unstructured":"Japanese Society of Travel Health. Guideline for traveler\u2019s vaccine in 2010. Tokyo: Kyowa publishing; 2010."},{"key":"2022091918195049157_j_med-2021-0303_ref_002","unstructured":"Center for Disease Control and Prevention. Yellow book 2020. New York: Oxford University Press; 2019."},{"key":"2022091918195049157_j_med-2021-0303_ref_003","doi-asserted-by":"crossref","unstructured":"Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51\u201363.","DOI":"10.1016\/j.vaccine.2009.04.063"},{"key":"2022091918195049157_j_med-2021-0303_ref_004","doi-asserted-by":"crossref","unstructured":"Villena R, Safadi MAP, Valenzuela MT, Torres JP, Finn A, O\u2019Ryan M. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother. 2018;14:1042\u201357.","DOI":"10.1080\/21645515.2018.1458175"},{"key":"2022091918195049157_j_med-2021-0303_ref_005","doi-asserted-by":"crossref","unstructured":"World Health Organization Null. Rabies vaccines: WHO position paper, April 2018 \u2013 recommendations. Vaccine. 2018;36:5500\u20133.","DOI":"10.1016\/j.vaccine.2018.06.061"},{"key":"2022091918195049157_j_med-2021-0303_ref_006","doi-asserted-by":"crossref","unstructured":"Thapa R, Banskota N, Pokharel J, Subedi BH, Basnyat B. Another typhoid patient from Japan. J Travel Med. 2010;17:199\u2013200.","DOI":"10.1111\/j.1708-8305.2010.00394.x"},{"key":"2022091918195049157_j_med-2021-0303_ref_007","doi-asserted-by":"crossref","unstructured":"Basnyat B, Pokhrel G, Cohen Y. The Japanese need travel vaccinations. J Travel Med. 2000;7:37.","DOI":"10.2310\/7060.2000.00011"},{"key":"2022091918195049157_j_med-2021-0303_ref_008","doi-asserted-by":"crossref","unstructured":"Yaita K, Yahara K, Hamada N, Sakai Y, Iwahashi J, Masunaga K, et al. Typhoid vaccination among Japanese travelers to South Asia and the factors associated with compliance. Intern Med. 2018;57:1071\u20134.","DOI":"10.2169\/internalmedicine.9405-17"},{"key":"2022091918195049157_j_med-2021-0303_ref_009","doi-asserted-by":"crossref","unstructured":"Yoon SH, Kim HW, Ahn JG, Kim IT, Kim JH, Kong KA, et al. Reappraisal of the immunogenicity and safety of three hepatitis A vaccines in adolescents. J Korean Med Sci. 2016;31:73\u20139.","DOI":"10.3346\/jkms.2016.31.1.73"},{"key":"2022091918195049157_j_med-2021-0303_ref_010","doi-asserted-by":"crossref","unstructured":"Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis. 1999;18:609\u201320.","DOI":"10.1007\/s100960050361"},{"key":"2022091918195049157_j_med-2021-0303_ref_011","doi-asserted-by":"crossref","unstructured":"Park H-J, Kim SJ, Song R, Chen J, Kim JH, Devadiga R, et al. A 6-year prospective, observational, multi-center post-marketing surveillance of the safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in Korea. J Korean Med Sci. 2019;34:e105.","DOI":"10.3346\/jkms.2019.34.e105"},{"key":"2022091918195049157_j_med-2021-0303_ref_012","doi-asserted-by":"crossref","unstructured":"Toovey S. Preventing rabies with the Verorab vaccine: 1985\u20132005 twenty years of clinical experience. Travel Med Infect Dis. 2007;5:327\u201348.","DOI":"10.1016\/j.tmaid.2007.07.004"},{"key":"2022091918195049157_j_med-2021-0303_ref_013","doi-asserted-by":"crossref","unstructured":"Fujiya Y, Takeshita N, Kanagawa S, Yamamoto K, Mawatari M, Kutsuna S, et al. Safety and adverse events following Measles, Mumps, and Rubella (MMR) vaccination in adults in Japan. Kansenshogaku Zasshi. 2016;90:518\u20139 (article in Japanese).","DOI":"10.11150\/kansenshogakuzasshi.90.518"},{"key":"2022091918195049157_j_med-2021-0303_ref_014","doi-asserted-by":"crossref","unstructured":"Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J. 2011;30:e56\u201362.","DOI":"10.1097\/INF.0b013e31820e6e02"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0303\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T18:36:54Z","timestamp":1663612614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0303\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,5,21]]},"published-print":{"date-parts":[[2021,5,21]]}},"alternative-id":["10.1515\/med-2021-0303"],"URL":"https:\/\/doi.org\/10.1515\/med-2021-0303","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}